Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Debt to Equity (2020 - 2025)

Eton Pharmaceuticals' Debt to Equity history spans 6 years, with the latest figure at $1.31 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 408.72% year-over-year to $1.31; the TTM value through Sep 2025 reached $1.31, up 408.72%, while the annual FY2024 figure was $1.22, 251.07% up from the prior year.
  • Debt to Equity for Q3 2025 was $1.31 at Eton Pharmaceuticals, up from $1.26 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.31 in Q3 2025 and bottomed at $0.02 in Q1 2021.
  • The 5-year median for Debt to Equity is $0.09 (2023), against an average of $0.34.
  • The largest annual shift saw Debt to Equity dropped 23.9% in 2022 before it surged 408.72% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.08 in 2021, then fell by 1.79% to $0.08 in 2022, then surged by 340.08% to $0.35 in 2023, then skyrocketed by 251.07% to $1.22 in 2024, then grew by 7.6% to $1.31 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Debt to Equity are $1.31 (Q3 2025), $1.26 (Q2 2025), and $1.22 (Q4 2024).